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Abstract 
Background: Cancer-related obstruction of large abdominal and pelvic veins might become 
symptomatic with clinical signs of lower limb venous congestion. Technical and clinical 
outcome after interventional treatment is not well studied yet. 
Purpose: To retrospectively assess the technical and clinical outcome of endovascular 
management of symptomatic cancer-related iliocaval venous obstructive disease. 
Material and Methods: From 1998 to 2013,  nineteen patients (15 men, 4 women; mean age 
63.6 years) were referred for interventional treatment of cancer-related iliocaval obstructive 
disease were identified. Patients’ symptoms included unilateral (n=16; 84%) or bilateral (n=3; 
16%) painful swelling of the lower limbs. Patients’ demographics as well as interventional 
and clinical outcome data were collected. 
Results: All 19 patients underwent, under local anesthesia, stenting of the iliac vein (n=16; 
84%) or inferior vena cava (n=3; 16%). Immediate technical success (n=19) was 100%; 
immediate clinical success (n=18) was 94.7%. During follow-up, 7 patients (36.8%) presented 
with recurrent symptoms of painful limb swelling. Estimated survival after 3 and 6 months 
was 68.4% (95% confidence interval 47.8% - 82.3%) and 19.8% (95% confidence interval 
11.9% - 29.2%) respectively. 
Conclusion: Endovascular stenting of cancer-related iliocaval venous obstructive disease is 
safe and results in immediate relief of symptoms. However, recurrent venous obstruction is 
common. At 3 months follow-up, the majority of patients with iliac vein stenting were still 
alive. 
Key words: vascular; interventional; stents; retroperitoneum; adults; primary neoplasms 
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Introduction 
Symptomatic obstruction related to malignant involvement of large veins may occur both in 
the central thoracic veins (1) and in the pelvic and abdominal region (2-4). Malignant iliac 
vein and inferior vena cava obstruction may result in debilitating symptoms of painful leg 
swelling, sometimes associated with penile, scrotal and preputial edema or anterior abdominal 
wall collaterals (5,6). However, published data on the diagnosis and interventional treatment 
of symptomatic iliocaval cancer-related obstruction are scarce and mainly consist of case 
reports and small case series (3,4,7-11), or deal with a mixed patient population presenting 
with malignant or benign venous obstructive disease (2,6). In addition, these few brief reports 
focus on the interventional technique to manage these venous compressions and its immediate 
clinical outcome, but data on overall survival and analysis of recurrent venous obstruction are 
frequently lacking. In this retrospective analysis, data were collected on patients presenting 
with cancer-related iliocaval venous obstruction treated with percutaneous, interventional 
radiological techniques. Finally, overall survival, recurrent venous obstruction and factors 
potentially influencing outcome were analyzed. 
 
Material and Methods 
Study design 
This is a retrospective study including patients referred to the department of interventional 
radiology of a tertiary care university hospital from January 2000 to January 2013. Approval 
4 
 
for the study was obtained from the institutional ethics committee (S 56056) and informed 
consent was obtained from all patients prior to the interventional procedure. 
Technique of venous stenting 
All endovascular procedures were performed under local anesthesia. Depending on the 
involved vein, the right or left common femoral vein or ipsilateral popliteal vein was 
punctured and an 8 or 10 French (F) sheath was introduced. The venous access was always 
achieved under ultrasound guidance. After intravenous administration of 5000 international 
units (IU) of unfractioned heparin, nonionic iodized contrast medium iopromide (Ultravist-
240, Bayer-Schering Health Care, Diegem, Belgium) was injected through the sheath in order 
to identify the venous obstruction. In the event of renal insufficiency or allergy to iodized 
contrast medium, carbon dioxide injected through a hand injection system (CO2-set, Optimed, 
Ettlingen, Germany) was used. Recanalization of the obstruction was typically performed 
with the use of a 0.035 inch hydrophilic guide wire (Glidewire, Terumo Europe, Leuven, 
Belgium) and a 4 or 5 F diagnostic catheter. If concomitant iliofemoral deep venous 
thrombosis was detected, catheter-directed thrombolysis using Urokinase (Actosolv, 
Eumedica, Brussels, Belgium) was performed. The infusion schema included an upload dose 
of 960.000 international units (IU) over 4 hours followed by a continuous infusion of 120.000 
IU per hour. Daily venographic controls are performed until less than 5% of residual 
thrombus is seen on venography. All malignant obstructive lesions were primarily stented 
with the use of self-expanding stents (Easy Wallstent, Boston Scientific, Natick, MA, USA; 
Zilver stent, Cook Medical, Bjaeverskov, Denmark; Memotherm, BARD-Angiomed, 
Karlsruhe, Germany). The diameter of the self-expanding stents was oversized with 1-2mm to 
the vein diameter below and above the underlying stenosis. Postdilatation of the stents was 
performed with conventional angioplasty balloon catheters with the same diameter as the vein 
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below and above the underlying stenosis to avoid overdilatation and venous rupture. Post-
dilation of the stents was performed with conventional angioplasty balloon catheters with the 
same diameter as the vein diameter below and above the underlying stenosis to avoid 
overdilatation and venous rupture. In the event of significant stent recoil after repeated 
postdilation, an additional balloon-expandable stent (Scuba, Invatec-Medtronic, Roncadelle, 
Italy) was inserted within the self-expanding stent. After completion venography of the 
stented segment, the vascular sheath was removed and manual compression of the puncture 
site performed. Therapeutic low molecular weight heparin (LMWH) was administered 
subcutaneously for the first 24 hours after stenting. Afterwards, therapeutic LMWH was 
prescribed for one month. Continued therapeutic LMWH administration was based on the 
patient’s comorbidities, the general status and the risk for paraneoplastic venous thrombosis. 
Follow-up 
All patients were followed up clinically by the referring oncologist and general practitioner 
until March 2013 or the patient’s death. Assessment of the clinical outcome and survival was 
performed based on the electronic medical records and telephone calls to the general 
practitioner. Radiological follow-up was available if the underlying malignant disease was re-
evaluated by imaging.  
Statistical analysis 
Kaplan-Meier estimates were used to construct survival curves. All analyses were performed 
using SAS software, version 9.2 of the SAS System for Windows (SAS Institute Inc., Cary, 
NC, USA). 
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Results 
Study population 
Nineteen patients (15 men, 4 women) with a mean age of 63.6 years (standard deviation 12.8 
years, min: 31.6 years; max: 92.4 years) were included in the study. Patients’ symptoms, 
affected veins, primary cancer and type of tumor mass compressing the affected vein are 
summarized in Table 1. 
Radiological examinations prior to interventional treatment included duplex-ultrasound (n=9), 
computed tomography (CT) (n=18) and magnetic resonance imaging (MRI) (n=1) showing a 
mass lesion compressing or invading the inferior vena cava (n=3) or iliac vein (n=16). In 2 
patients, catheter-directed thrombolysis of the acute iliofemoral deep venous thrombosis, 
localized over the whole iliac axis, was performed prior to the stent procedure. Total dose of 
Urokinase infused was respectively 900.000 IU and 1.200.000 IU. Finally, insertion of self-
expanding stents was performed to treat the underlying venous obstruction. 
Technical outcome 
All procedures were performed under local anesthesia. In 18 out of 19 patients, the common 
femoral vein was punctured and in the remaining patient, the ipsilateral popliteal vein was 
punctured because of extensive tumor invasion of the external iliac vein and the proximal part 
of the common femoral vein. In 3 patients, a contralateral approach was performed, in 12 
patients the ipsilateral common femoral vein was punctured and in the 3 patients with inferior 
vena cava obstruction, the right common femoral vein was selected. 
Venography was performed in 2 patients (11%) with the use of carbon dioxide (CO2) (Fig. 1) 
because of renal impairment; in the remaining 17 patients (89%), iodized contrast medium 
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was used. Venography revealed a complete occlusion of the involved vein in 2 patients 
(11%); in 17 patients a severe stenosis > 90% was observed (Fig. 2). Guide wire 
recanalization and stent placement was successful in all cases. In 6 patients, an Easy Wallstent 
with a nominal diameter of 14 or 16 mm was inserted; in 9 patients, a Zilver stent with a 
nominal diameter of 12 or 14 mm was inserted; in the remaining patient with an inferior vena 
cava occlusion, a Memotherm with a nominal diameter of 20 mm was placed. 
In one patient, a balloon-expandable Scuba stent, 4 cm in length and 10 mm in diameter was 
placed within the Zilver stent for complete re-expansion of the stented iliac vein segment. 
Completion venography showed re-expansion of all stented segments with a < 30% residual 
stenosis. No peri- or immediate postprocedural complications were noted. 
Clinical outcome 
Initial clinical symptoms of painful leg swelling disappeared in 18 patients (95%) within the 
first 3 days after the stent procedure. One patient with an initial obstruction of the inferior 
vena cava did not respond clinically to the technically successful endovascular stent 
placement, with major residual bilateral lower limb swelling. 
During follow-up, in 7 patients (37%) 8 events of recurrent leg swelling related to stent 
restenosis or occlusion were noted, as demonstrated by ultrasound or CT: the time intervals 
after initial stent procedure and additional treatment are summarized in Table 2. No stent 
crush was noted in any of the retreated patients. In 3 patients presenting with thrombotic stent 
occlusion, it was decided to treat this event conservatively by the administration of low 
molecular weight heparin (LMWH) without additional stenting, in view of the patient’s poor 
general condition and the terminal phase of the cancer. 
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The overall survival of the study patient population is summarized in Table 3 and Fig. 3. 17 
patients died during follow-up; 2 patients were still alive at the end of the study follow-up 
(March 2013).  
 
Discussion 
This study shows that percutaneous stent insertion for the palliative treatment of patients with 
symptomatic cancer-related venous iliocaval obstructive disease is safe and effective, with a 
very high rate of immediate, symptomatic relief. The use of stents instead of balloon 
angioplasty alone is strictly required to avoid immediate recoil of the vein wall by the 
compressing tumoral mass lesion. These results are in line with published data showing 
immediate symptom relief in 80% - 100% of cases (2-4,7,8). In this series, no peri- or 
immediate post-procedural complications, in particular stent fracture or stent migration, were 
noted. Nazarian et al. (2) reported two out of 56 cases of stent fracture and 4 cases of stent 
slippage in patients presenting with both malignant and benign iliofemoral venous 
obstructions. They all occurred in patients treated with Gianturco-Rösch-Z-stents. These 
authors (2) as well as others (3,6), did not report similar complications when using Wallstents 
or nitinol-based self-expanding stents, and these findings are confirmed by this study. One out 
of 9 patients treated with a Cook Zilver nitinol stent for a malignant external left iliac vein 
stenosis required an additional balloon-expandable stent to completely open the self-
expanding nitinol stent. The need for an additional stent with a high radial force was also 
found in 22% of patients treated for malignant superior vena cava syndrome (1). 
In this series, the majority of patients presenting with malignant iliac vein occlusion suffered 
from widespread metastatic urogenital cancers (n=10; 62.5%). In a minority of patients, 
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lymph node metastasis from other cancers, including rectal carcinoma and breast carcinoma, 
was responsible for the malignant venous involvement. These findings, based on a larger 
patient population, confirm the preliminary data of Tacke et al. (8) and Wilhelm et al. (7). 
Although immediate clinical success is very high, the rate of recurrent venous obstruction in 
this series is also relatively high: 37% clinical relapse over a relatively short median follow-
up interval of 5.23 months. Furthermore, a systematic radiological control for evaluation of 
stent patency was not performed, which may suggest that the in-stent restenosis ratio may be 
even higher, given that most of the patients were in the terminal phase of their disease and 
some may have been too frail or refused to be readmitted for stent re-evaluation. This 
relatively high re-occlusion rate may be explained by the hypercoagulable state or by tumor 
progression in or around the stents in this oncological patient group. A relatively high re-
occlusion rate in venous stents was also found by Nazarian et al. (2): a 50% overall primary 
patency rate at one year in a patient population with mixed benign and malignant iliac vein 
stenoses. Moreover, these authors also found statistically higher secondary patency rates in 
benign disease than in patients with malignant disease (P=0.05). Treatment of in-stent 
restenosis can be performed by balloon angioplasty with or without re-stenting; catheter-
directed thrombolysis in the event of complete stent thrombosis may be an alternative option 
if there are no contraindications for thrombolysis. In oncological patients, it is important to 
exclude the presence of brain or spinal metastases, even if these metastases are asymptomatic, 
before initiating the thrombolysis, as demonstrated in a series of catheter-directed 
thrombolysis of thoracic deep venous thrombosis (12). Mechanical thrombectomy may be a 
valuable alternative to pharmacological thrombolysis in this subgroup of patients. 
In case of allergy to iodized contrast medium or in case of renal function impairment, CO2 
can be safely used instead of dye without any risk for pulmonary or other side effects as 
10 
 
demonstrated by Heye et al. (13) for the mapping of upper limb veins in patients with 
preterminal renal insufficiency. 
The estimated overall survival rate at 3 months follow-up was 68% (confidence internal 47% 
- 82%); however, at 1 year follow-up these numbers decreased to nearly 20% (confidence 
interval 12% - 29%), stressing the fact that patients with symptomatic iliocaval malignant 
obstruction have a limited prognosis. When the obstruction is at the level of the inferior vena 
cava, the survival rate might be even less: in this series, all 3 patients stented for malignant 
inferior vena cava obstruction died within 3 months of the procedure. Brountzos et al. (3) 
found a median follow-up at 62 days after intrahepatic inferior vena cava stenting. It is not 
clear why the prognosis is worse than for patients with malignant iliac vein obstruction. 
However, the type of underlying malignancy (primary hepatic cancers versus urogenital 
cancers), the extent of the tumoral mass or the potential chemotherapeutic treatment options 
may be different for tumors invading the inferior vena cava versus tumors invading the iliac 
vein. 
Finally, given the minimal invasiveness of the procedure associated with immediate symptom 
relief, the low morbidity of the procedure and the possibility of withdrawing a patient, we 
believe that iliocaval stenting is a meaningful and minimally invasive palliative intervention 
for patients with debilitating symptoms of venous obstruction, despite the relatively high 
symptomatic in-stent restenosis rate, especially in patients with a life expectancy of at least 
3 months. 
In conclusion, in this series it is demonstrated that palliative, endovascular treatment of 
symptomatic, malignant iliocaval obstructive disease is safe and effective, with immediate 
relief of symptoms in the large majority of patients. However, a relatively high rate of 
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recurrent venous obstruction is to be expected related to in-stent occlusion, and overall 
survival is limited, in particular in patients with inferior vena cava involvement. 
12 
 
Conflict of Interest Statement: None. 
  
13 
 
References 
1. Maleux G, Gillardin P, Fieuws S, et al. Large-bore nitinol stents for malignant superior 
vena cava syndrome: factors influencing outcome. Am J Roentgenol 2013; 201: 667-674. 
2. Nazarian G, Bjarnason H, Dietz C, et al. Iliofemoral venous stenoses: Effectiveness of 
treatment with metallic endovascular stents. Radiology 1996; 200: 193-199. 
3. Brountzos E, Binkert C, Panagiotou I, et alP. Clinical outcome after intrahepatic venous 
stent placement for malignant inferior vena cava syndrome. Cardiovasc Intervent Radiol 
2004; 27: 129-136. 
4. Fletcher W, Lakin P, Pommier R, et al . Results of treatment of inferior vena cava 
syndrome with expandable metallic stents. Arch Surg 1998; 133: 935-938. 
5. Zamora C, Sugimoto K, Mori T, et al. Use of the wallstent for symptomatic relief of 
malignant inferior vena cava obstructions. Radiat Med 2005; 23: 380-385. 
6. Razavi M, Hansch E, Kee S, et al . Chronically occluded inferior venae cavae : 
endovascular treatment. Radiology 2000; 214: 133-138. 
7. Wilhelm K, Schild H, Bruch E, et al. Stent implantation as palliative therapeutic measure 
in malignant venous obstruction. Rofo 1995; 162: 514-520. 
8. Tacke J, Antonucci F, Stuckmann G, et al. Palliative treatment of venous stenoses in 
tumour patients with self-expanding stents. Rofo 1994; 160: 433-440. 
9. Hama Y, Kaji T, Hayakawa M, et al. Endovascular stent placement for malignant 
stenosis and occlusion of bilateral iliac veins and inferior vena cava after failure of 
radiation therapy. Minimally Invasive Therapy 2005; 14: 372-375. 
10. Entwisle K, Watkinson A, Hibbert J, et al. The use of the Wallstent endovascular 
prosthesis in the treatment of malignant inferior vena cava obstruction. Clin Radiol 1995; 
50: 310-313. 
14 
 
11. Gasparis AP, Kokkosis A, Labropoulos N. Venous outflow obstruction with 
retroperitoneal Kaposi’s sarcoma and treatment with inferior vena cava stenting. Vasc 
Endovascular Surg 2009;43: 295-300. 
12. Maleux G, Marchal P, Palmers M, et al. Catheter-directed thrombolytic therapy for 
thoracic deep vein thrombosis is safe and effective in selected patients with and without 
cancer. Eur Radiol 2010; 20: 2293-300. 
13. Heye S, Maleux G, Marchal G. Upper-extremity venography: CO2 versus iodinated 
contrast material. Radiology 2006;241: 291-297. 
  
15 
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Fig. 3 
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Figure legends 
 
Fig. 1. A 78-year-old woman presented with a painful and swollen left lower limb;  (a) 
axial and (b) reconstructed coronal contrast enhanced CT-images revealed a hypodense 
mass lesion (arrows). The mass lesion was a necrotic lymph node of a urethral 
transitional cell carcinoma and invaded the left external iliac vein;  (c) corresponding 
venography confirmed the malignant occlusion of the external iliac vein;  (d) 
recanalization and stenting of the occluded segment resulted in restored iliac venous 
patency. 
Fig. 2. A 55-year-old man with a history of metastatic prostate carcinoma presented 
with a painful left swollen lower limb;  (a) CT scan demonstrated a hypodense mass 
lesion in close proximity to the left iliac vein;  (b) corresponding left iliac venography 
showed a focal high-grade stenosis owing to malignant invasion of the malignant lymph 
nodes;  (c) after stent placement, a restored patency of the left venous iliac axis was 
demonstrated. 
Fig. 3: The Kaplan-Meier overall survival curve demonstrates an estimated survival 
percentage (95% confidence interval) of 68.4% (47.8% - 82.3%) and 19.8% (11.9% - 
29.2%) at 3 and 12 months follow-up respectively. 
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Table 1: Patient demographics 
 
Patient’s symptoms     number %  
painful swelling of the right lower limb   n=7  37% 
painful swelling of the left lower limb   n=9  47% 
bilateral painful lower limb swelling   n=3  16% 
 
Patient’s initial cancer 
transitional cell carcinoma of the urethra   n=1  5.3% 
prostate carcinoma      n=6  31.6% 
transitional cell carcinoma of the bladder   n=2  10.2% 
non-small-cell lung carcinoma    n=1  5.3% 
breast carcinoma      n=1  5.3% 
adenocarcinoma of the rectum    n=4  21.1% 
penile carcinoma      n=1  5.3% 
hepatocellular carcinoma     n=1  5.3% 
soft tissue sarcoma      n=1  5.3% 
unknown       n=1  5.3% 
 
Affected vein 
External iliac vein     n=12  63.2% 
Common iliac vein     n=4  21.1% 
Inferior vena cava     n=3  15.8% 
 
Type of tumor mass compressing the affected vein  
Primary tumor     n=2  10.2% 
Adenopathies      n=17  89.5% 
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Table 2: Late complications of stent re-occlusion 
 
 
Patient  time interval after initial stenting  re-treatment    
Pt 1   10 months    conservative: LMWH 
Pt 2   3 months    re-stenting 
Pt 3   8 months    conservative: LMWH 
Pt 4   1 month    re-stenting 
Pt 4   3 months    CDT  
Pt 5   2 months    conservative: LMWH 
Pt 6   6 months    re-stenting 
Pt 7   1 month    re-stenting 
 
 
 
 
 
LMWH: low molecular weight heparin 
CDT: catheter-directed thrombolysis 
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Table 3: Estimated survival percentages (+95% confidence interval) 
 
 
 
Months survival lower limit upper limit 
1  84.21  61.50  94.11 
3  68.42  47.78  82.28 
12  19.85  11.97  29.17 
24    6.62    3.90  10.31 
 
